Skip to main content
Premium Trial:

Request an Annual Quote

Aw, A Success

A Forbes article entitled, “Genomics: No Longer A Failure,” says that Human Genome Sciences and Vertex Pharmaceuticals are finally living up to the hype promised during Human Genome Project. Human Genome saw positive results in a second study of its lupus drug, Benlysta, and Vertex presented mid-stage results of its hepatitis C drug, telaprevir, that indicated it could work as well if taken twice a day as three times a day, which is how it is currently being tested. Forbes notes that Benlysta would be “one of the first [drugs] to emerge from newfangled efforts to decipher the human genome that started in the early 1990s, amid enormous amounts of hype that it would lead to a huge cornucopia of new drugs.”

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.